Avanovi Medical, founded by Mark Moran, specializes in strategic consulting for the radiopharmaceutical and nuclear medicine industry. With over two decades of experience, Mark has led business expansion initiatives, secured multimillion-dollar investments, and optimised supply chains to support the growth of life-saving therapies.

Mark – A Leader in Radiopharmaceutical Innovation

With over 25 years of experience in the pharmaceutical and radiopharmaceutical industries, Mark built a distinguished career advancing nuclear medicine, medical isotopes, and radiopharmaceutical development. From his early roles in pharmaceutical science and manufacturing to leadership positions in market expansion, investment strategy, and business development, he played a pivotal role in shaping industry advancements.

Throughout his career, Mark led market expansion efforts, secured significant investments, and optimised manufacturing and supply chains. His expertise in regulatory strategy, strategic partnerships, and operational efficiency contributed to the growth and success of numerous radiopharmaceutical ventures.

Career Highlights

• Expanded Market Access & Growth – Spearheaded initiatives that increased the availability and adoption of radiopharmaceuticals worldwide.
• Secured Investment & Built Strategic Partnerships – Led multimillion-dollar funding efforts and developed collaborations that drove industry growth.
• Optimised Manufacturing & Supply Chains – Implemented strategies to enhance efficiency, regulatory compliance, and scalability.
• Navigated Regulatory & Market Access Challenges – Successfully addressed pricing, reimbursement, and compliance barriers to ensure market success.

Over the course of his career, Mark collaborated with industry leaders, investors, and regulatory bodies, helping to shape the radiopharmaceutical landscape. His passion for innovation, problem-solving, and strategic leadership defined his professional journey, leaving a lasting impact on the industry.

Throughout his career, he has held leadership roles at industry-leading companies, including Urenco Group, Curium Pharma, Mallinckrodt Pharmaceuticals, and Covidien Healthcare. 

Mark’s career began as a radiopharmaceutical scientist at Great Ormond Street Hospital, where he gained hands-on experience in clinical pharmaceutical services and radioactive drug preparation. He later went on to become Director of Radiopharmacy (a commercial inplant) at the Institute of Nuclear Medicine, University College London Hospital. 

He holds a B.Sc. (Hons) in Biology and an FdSc in Pharmacy Services. He has further strengthened his leadership and financial acumen through executive programs at Columbia Business School and London Business School.